LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Inicio・Lista de Acciones・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Cerrado

SectorSalud

442.08 1.09

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

441.06

Máximo

445.7

Métricas clave
By Trading Economics
Ingresos	56M -59M
Ventas	34M 321M
Margen de beneficio	-18.243
Empleados	915
EBITDA	56M -50M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+56.84% upside

Dividendos
By Dow Jones
Próximas Ganancias	30 abr 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-716M 9.8B
Apertura anterior	440.99
Cierre anterior	442.08

Noticias sobre sentimiento de mercado

By Acuity

44%

56%

125 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

263.2 / 277.1 Soporte y Resistencia

Madrigal Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 mar 2026, 19:08 UTC

Noticias de Eventos Importantes

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

13 mar 2026, 18:48 UTC

Ganancias

Principales Movimientos del Mercado

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

13 mar 2026, 17:10 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

13 mar 2026, 17:10 UTC

Noticias de Eventos Importantes

Week Ahead for FX, Bonds: Central Bank Decisions -2-

13 mar 2026, 16:47 UTC

Noticias de Eventos Importantes

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

14 mar 2026, 15:00 UTC

Noticias de Eventos Importantes

Iran War Delivers Windfall to America's Oil Country -- WSJ

14 mar 2026, 02:03 UTC

Ganancias

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14 mar 2026, 01:32 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14 mar 2026, 00:29 UTC

Adquisiciones, fusiones, absorciones

13D Filings -- Barrons.com

13 mar 2026, 22:27 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13 mar 2026, 22:13 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13 mar 2026, 22:04 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13 mar 2026, 22:00 UTC

Adquisiciones, fusiones, absorciones

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

13 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

13 mar 2026, 20:02 UTC

Charlas de Mercado

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13 mar 2026, 19:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13 mar 2026, 19:35 UTC

Noticias de Eventos Importantes

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

13 mar 2026, 19:00 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

13 mar 2026, 18:49 UTC

Noticias de Eventos Importantes

The Iran War Could Upend AI. Here's How. -- Barrons.com

13 mar 2026, 18:24 UTC

Noticias de Eventos Importantes

Impact of Middle East Conflict on TotalEnergies Activities

13 mar 2026, 18:00 UTC

Noticias de Eventos Importantes

Is War Good For the Economy? -- WSJ

13 mar 2026, 17:23 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

13 mar 2026, 16:46 UTC

Charlas de Mercado

Noticias de Eventos Importantes

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

13 mar 2026, 16:38 UTC

Noticias de Eventos Importantes

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

13 mar 2026, 16:34 UTC

Adquisiciones, fusiones, absorciones

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

13 mar 2026, 16:33 UTC

Adquisiciones, fusiones, absorciones

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

13 mar 2026, 16:32 UTC

Adquisiciones, fusiones, absorciones

EQT Completes Exit From Galderma

13 mar 2026, 16:20 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

13 mar 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Madrigal Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

56.84% repunte

Estimación a 12 meses

Media 697.67 USD 56.84%

Máximo 964 USD

Mínimo 529 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Madrigal Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Madrigal Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

263.2 / 277.1Soporte y Resistencia

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

125 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.